Ken Graves, a healthcare industry veteran and expert on medtech and supply chain, has been elected to the OpenMarkets Board of Directors.
OpenMarkets, a marketplace for healthcare equipment, is a rapidly growing community taking waste out of the buying and selling of medical equipment. Graves’ expertise on evaluating the strategic impact of consolidation and innovation position him to assist the OpenMarkets leadership team in bringing the healthcare providers and suppliers to the OpenMarkets Community.
“Ken’s intellect and healthcare insight is an asset for us,” said Michael Fineberg, CEO at OpenMarkets. “He has a deep understanding of the challenges equipment suppliers and health systems face in working together. Bridging this divide is what OpenMarkets does. With Ken on our Board, we will now be more thoughtful and impactful in how we create financial benefits for suppliers and providers.”
Graves advised global medtech firms and health systems on growth strategies for 11+ years as a Managing Director at L.E.K. Consulting. He retired from L.E.K. in early 2018, with 30 total years of healthcare experience under his belt.
Graves will join Alan Weinstein, Founder and former CEO of Premier, as public members on the OpenMarkets Board.
“OpenMarkets is successfully disrupting a tough industry,” said Weinstein. “As we grow, the challenges to market penetration will change. Ken’s successfully coached executives on growth strategy for years, and his guidance will allow the OpenMarkets executive team to keep up the rapid growth as they begin working with the majority of U.S. healthcare providers.”
“I’m excited to dive in with Michael, the Board and the management team,” said Graves. “OpenMarkets is disrupting healthcare’s capital supply chain space in a high impact way that is clearly beyond what Group Purchasing Organizations and other firms can offer. They’re driving out waste for suppliers and improving the bottom line for health systems and patient care facilities. Smart growth is very difficult, and I’m in the fortunate position of having developed strategy with medtech innovators who’ve successfully expanded to meet a market need. It’s going to be fun to tackle this challenge with the team.”